Cambridge Investment Research Advisors
ACRS icon

Cambridge Investment Research Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Hold
41,873
– – ﹤0.01% 3727
2025
Q4 		$126K Hold
41,873
– – ﹤0.01% 3670
2025
Q3 		$80K Hold
41,873
– – ﹤0.01% 3612
2025
Q2 		$59K Hold
41,873
– – ﹤0.01% 3522
2025
Q1 		$64K Hold
41,873
– – ﹤0.01% 3390
2024
Q4 		$104K Hold
41,873
– – ﹤0.01% 3324
2024
Q3 		$48K Hold
41,873
– – ﹤0.01% 3334
2024
Q2 		$46K Hold
41,873
– – ﹤0.01% 3222
2024
Q1 		$52K Hold
41,873
– – ﹤0.01% 3208
2023
Q4 		$44K Buy
41,873
+26,535
+173% +$81K ﹤0.01% 3107
2023
Q3 		$105K Hold
15,338
– – ﹤0.01% 2956
2023
Q2 		$159K Hold
15,338
– – ﹤0.01% 2936
2023
Q1 		$124K Hold
15,338
– – ﹤0.01% 2927
2022
Q4 		$242K Sell
15,338
-200
-1% -$3.22K ﹤0.01% 2600
2022
Q3 		$245K Buy
15,538
+200
+1% +$3.15K ﹤0.01% 2535
2022
Q2 		$214K Hold
15,338
– – ﹤0.01% 2677
2022
Q1 		$264K Hold
15,338
– – ﹤0.01% 2650
2021
Q4 		$223K Hold
15,338
– – ﹤0.01% 2782
2021
Q3 		$276K Buy
15,338
+638
+4% +$10.2K ﹤0.01% 2529
2021
Q2 		$258K Hold
14,700
– – ﹤0.01% 2586
2021
Q1 		$370K Sell
14,700
-30,073
-67% -$588K ﹤0.01% 2131
2020
Q4 		$290K Buy
44,773
+73
+0.2% +$308 ﹤0.01% 2171
2020
Q3 		$115K Hold
44,700
– – ﹤0.01% 2373
2020
Q2 		$72K Hold
44,700
– – ﹤0.01% 2351
2020
Q1 		$46K Hold
44,700
– – ﹤0.01% 2185
2019
Q4 		$84K Hold
44,700
– – ﹤0.01% 2327
2019
Q3 		$48K Buy
+44,700
New +$63.4K ﹤0.01% 2283

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cambridge Investment Research Advisors's ACRS Position: Q1 2026 in Review

Cambridge Investment Research Advisors held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 41,873 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #3727.

Cambridge Investment Research Advisors first reported a position in ACRS in Q3 2019 and has held it in 27 quarters since. The position peaked at $370K in Q1 2021. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Cambridge Investment Research Advisors held 41,873 shares of Aclaris Therapeutics worth $157K as of Q1 2026.
  • Cambridge Investment Research Advisors left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3727 holding.
  • Cambridge Investment Research Advisors first reported a position in Aclaris Therapeutics in Q3 2019 and has held it in 27 quarters since.
  • Cambridge Investment Research Advisors's Aclaris Therapeutics position peaked at $370K in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.